By Camilla Lindgren, Security of supply program leader, Cytiva, Mike Toner, Global product manager, Cytiva, and Fredrik Lundström, Global product manager, Cytiva
Biopharmaceutical companies need to be able to more efficiently deliver their therapies to patients.
The use of single-use technologies has been steadily increasing over the past decade, led by upstream operations and trends with emerging therapy developers, such as cell and gene therapy and vaccine adjuvants.
However, implementing single-use technologies can be complex. Some challenges include customization requirements and accurate forecasting. Supply constraint has been a key obstacle.
This article explores why single-use technology is growing at such a rapid pace, the challenges with single-use technologies, the importance of dialogue and forecasting, and the path forward for the future of single-use supply.